Enveric Biosciences, Inc.
ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid aā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.57
Price+9.79%
$0.14
1Y
Price
Market Cap
$937.309k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$8.220m
-1.6%
1y CAGR-18393.5%
3y CAGR-13779.6%
5y CAGREPS
-$27.34
-6318.4%
1y CAGR-2138.7%
3y CAGR-1582.1%
5y CAGRBook Value
$5.061m
$5.521m
Assets$460.680k
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$8.007m
+0.8%
1y CAGR+22.1%
3y CAGR+5.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company